ResearchBib Share Your Research, Maximize Your Social Impacts
Sign for Notice Everyday Sign up >> Login

2024 - A Collaborative Approach to Advancing Access and Equity in Rare Disease Clinical Trials

Date2024-02-29

Deadline2024-02-29

VenueONLINE-VIRTUAL, USA - United States USA - United States

KeywordsLife Sciences; Clinical Trials; Patient Recruitment & Retention

Websitehttps://xtalks.com/webinars/a-collaborat...

Topics/Call fo Papers

Ensuring that all patients have equal access to participate in clinical trials across all geographies has become essential throughout the industry. Patient recruitment and retention remain one of the most challenging hurdles in clinical development, particularly for rare diseases. Implementing a patient-focused clinical trial design and fostering a collaborative approach between the Sponsor, CRO, sites, and advocacy groups can help lead to successful clinical trials.
Given the daily obstacles faced by patients with rare diseases, including late onset Pompe disease, it is critical to minimize patient burden while recruiting a committed group of patients. Once recruited into a clinical study, it becomes paramount to provide ongoing support by focusing on the needs and concerns of the patient. This enhances patient retention, facilitating the collection of vital data for primary endpoints, which ultimately leads to faster therapies to market to give the patient community a treatment option.
In this webinar, Medpace, a global full-service CRO, will discuss the importance of equity in patient-friendly rare disease trials. Experts will discuss strategies in creating a positive clinical trial experience through a collaborative approach between sites, the Sponsor, and the CRO.
Register now for the Rare Disease Day 2024 webinar to join the discussion with clinical trial experts on a collaborative approach to patient-friendly trials in rare disease.
Keywords: Rare Disease, Drug Development, Clinical Research, CRO, Patient Recruitment, Rare Diseases, Therapeutic Areas, Rare Disease Trials, Patient Access, Patient Participation, Rare Disease Clinical Trials, Clinical Trial Access, Rare Diseases/Orphan Drugs

Last modified: 2024-01-30 07:36:38